Arcus Biosciences
RCUS
187 hedge funds and large institutions have $816M invested in Arcus Biosciences in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 70 increasing their positions, 70 reducing their positions, and 26 closing their positions.
89% more capital inflows, than outflows
Capital inflows: $102M | Capital outflows: $54.1M
72% more call options, than puts
Call options by funds: $3.79M | Put options by funds: $2.2M
1.24% more ownership
Funds ownership: 57.1% → 58.34% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 70
3% less funds holding
Funds holding: 193 → 187 (-6)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$9.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.5M |
| 3 |
Ikarian Capital
Dallas,
Texas
|
+$9.44M |
| 4 |
Schonfeld Strategic Advisors
New York
|
+$6.95M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodline Partners
San Francisco,
California
|
-$12.1M |
| 2 |
Laurion Capital Management
New York
|
-$6.56M |
| 3 |
Suvretta Capital Management
New York
|
-$4.63M |
| 4 |
Trexquant Investment
Stamford,
Connecticut
|
-$2.6M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.45M |
RCUS Hedge Fund Activity: Q3 2024 in Review
187 of the 6,986 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2024, worth a combined $816M — up 3.1% from $791M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of RCUS and 21 opened new positions — a net loss of 5 holders — while 70 trimmed existing stakes and 70 added.
The largest buyer was Parkman Healthcare Partners, adding an estimated $9.6M. The largest seller was Woodline Partners, cutting an estimated $12.1M.
- 187 institutional investors held Arcus Biosciences (RCUS) as of Q3 2024, down from 193 in Q2 2024.
- Funds reported $816M of Arcus Biosciences stock for Q3 2024, up 3.1% quarter-over-quarter.
- 21 funds opened new Arcus Biosciences positions in Q3 2024 and 26 closed out, a net change of -5 holders.
- The largest Arcus Biosciences buyer in Q3 2024 was Parkman Healthcare Partners, an estimated $9.6M added.
- The largest Arcus Biosciences seller in Q3 2024 was Woodline Partners, an estimated $12.1M sold.
Based on aggregated 13F filings for Q3 2024.